RXRX Earnings

Quarterly EPS
$-0.34
Q3 2024
$-0.53
Q4 2024
$-0.50
Q1 2025
$-0.41
Q2 2025
$-0.36
Q3 2025
$-0.21
Q4 2025
$-0.22
Q1 2026
$-0.25
Q2 2026
Latest Revenue7.7M
Latest Net Income-131005000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.257.7M-131005000-60.1%+39.0%
Q1 2026-$0.226.5M-117504000-56.1%+56.0%
Q4 2025-$0.2135.5M-108122000+681.7%+60.4%
Q3 2025-$0.365.2M-162253000-80.2%-5.9%
Q2 2025-$0.4119.2M-171897000+33.3%-2.5%
Q1 2025-$0.5014.7M-202487000+6.9%-28.2%
Q4 2024-$0.534.5M-178906000-58.3%-26.2%
Q3 2024-$0.3426.1M-95842000+147.6%+20.9%
Q2 2024-$0.4014.4M-97540000
Q1 2024-$0.3913.8M-91373000
Q4 2023-$0.4210.9M-92996000
Q3 2023-$0.4310.5M-93017000
Recursion Pharmaceuticals (RXRX) — Earnings